Literature DB >> 20231447

Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.

Xiaoying Shen1, S Moses Dennison, Pinghuang Liu, Feng Gao, Frederick Jaeger, David C Montefiori, Laurent Verkoczy, Barton F Haynes, S Munir Alam, Georgia D Tomaras.   

Abstract

The conserved membrane-proximal external region (MPER) of HIV-1 envelope is a target for the rare broadly neutralizing 2F5, Z13, and 4E10 monoclonal antibodies (mAbs). One strategy to elicit such antibodies is to design an immunogen with increased exposure of the 2F5 and 4E10 mAb epitopes. In this study we characterize a single leucine to serine substitution at position 669 (L669S) in the gp41 Env MPER that confers >250-fold more neutralization sensitivity to 2F5 and 4E10 mAbs than does the wild-type gp41 sequence. On synthetic liposomes, increased solvent exposure of MPER tryptophan residues and stable docking of 2F5 and 4E10 mAbs to mutant MPER peptide liposomes indicate more favorable membrane orientation of MPER neutralizing epitopes with L669S substitution. The time during which virus is sensitive to 2F5 mAb-mediated neutralization is approximately 3-fold longer when the mutation is present. These data suggest that a major contribution to the L669S mutant virus phenotype of enhanced susceptibility to MPER mAbs is prolonged exposure of the MPER neutralizing epitope during viral entry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231447      PMCID: PMC2851912          DOI: 10.1073/pnas.0912381107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.

Authors:  Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

2.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A.

Authors:  J E Robinson; D Holton; J Liu; H McMurdo; A Murciano; R Gohd
Journal:  J Immunol Methods       Date:  1990-08-28       Impact factor: 2.303

4.  Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.

Authors:  B A Watkins; S Buge; K Aldrich; A E Davis; J Robinson; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

Authors:  L Eckhart; W Raffelsberger; B Ferko; A Klima; M Purtscher; H Katinger; F Rüker
Journal:  J Gen Virol       Date:  1996-09       Impact factor: 3.891

6.  Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance.

Authors:  Laurent Verkoczy; Marilyn Diaz; T Matt Holl; Ying-Bin Ouyang; Hilary Bouton-Verville; S Munir Alam; Hua-Xin Liao; Garnett Kelsoe; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

7.  An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120.

Authors:  S Munir Alam; Casey A Paleos; Hua-Xin Liao; Richard Scearce; James Robinson; Barton F Haynes
Journal:  AIDS Res Hum Retroviruses       Date:  2004-08       Impact factor: 2.205

8.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression.

Authors:  G D Tomaras; S F Lacey; C B McDanal; G Ferrari; K J Weinhold; M L Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  45 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Authors:  Daniela Tudor; Huifeng Yu; Julien Maupetit; Anne-Sophie Drillet; Tahar Bouceba; Isabelle Schwartz-Cornil; Lucia Lopalco; Pierre Tuffery; Morgane Bomsel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

3.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

4.  Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.

Authors:  Nathan I Nicely; S Moses Dennison; Leonard Spicer; Richard M Scearce; Garnett Kelsoe; Yoshihiro Ueda; Haiyan Chen; Hua-Xin Liao; S Munir Alam; Barton F Haynes
Journal:  Nat Struct Mol Biol       Date:  2010-11-14       Impact factor: 15.369

5.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

6.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

7.  Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.

Authors:  Zhongyu Zhu; Haiyan Rebekah Qin; Weizao Chen; Qi Zhao; Xiaoying Shen; Robert Schutte; Yanping Wang; Gilad Ofek; Emily Streaker; Ponraj Prabakaran; Genevieve G Fouda; Hua-Xin Liao; John Owens; Mark Louder; Yongping Yang; Kristina-Ana Klaric; M Anthony Moody; John R Mascola; Jamie K Scott; Peter D Kwong; David Montefiori; Barton F Haynes; Georgia D Tomaras; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

8.  Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.

Authors:  S Munir Alam; Hua-Xin Liao; S Moses Dennison; Frederick Jaeger; Robert Parks; Kara Anasti; Andrew Foulger; Michele Donathan; Judith Lucas; Laurent Verkoczy; Nathan Nicely; Georgia D Tomaras; Garnett Kelsoe; Bing Chen; Thomas B Kepler; Barton F Haynes
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

9.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

10.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.